Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM103 + PD-1 in advanced solid tumors
NCT06697665Phase 1Recruiting
- Sponsor
- Suzhou BlueHorse Therapeutics
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LM103 in solid tumor, sponsored by Suzhou BlueHorse Therapeutics. Primary endpoint: Adverse events, Serious adverse event and immune related adverse events. Started Jan 2024; status: recruiting.
02
Drugs
LM103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06697665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06697665.